Abstract
Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Current Cancer Therapy Reviews
Title: Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Volume: 2 Issue: 2
Author(s): Gautam Sethi and Bharat B. Aggarwal
Affiliation:
Keywords: Chemoresistance, radioresistance, nuclear factor kappa B, chemosensitivity, radiosensitivity
Abstract: Resistance of tumor cells to chemotherapeutic agents and to radiation is one of the major obstacles in the treatment of human cancers. The exact mechanism by which cells develop resistance to chemotherapeutic and radiotherapeutic agents is not well understood. Accumulating evidences over the last decade suggests however that transcription factor nuclear factor-kappa B (NF-κ B) may play an important role in both chemoresistance and radioresistance. Three lines of evidence support this position. First, most chemotherapeutic agents and gamma radiation activate NF-κ B in vitro and in vivo. Second, induction of chemoresistance and radioresistance is mediated via genes regulated by NF-κ B. Third, inhibition of NF-κ B and NF-κ B-regulated gene products increases sensitivity of cancer cells to apoptotic action of chemotherapeutic agents and to radiation exposure. This review focuses on current knowledge of the regulation of resistance of tumors cells to chemotherapeutic agents and gamma radiation by NF-κ B and the therapeutic potential of targeting NF-κ B in cancer treatment.
Export Options
About this article
Cite this article as:
Sethi Gautam and Aggarwal B. Bharat, Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872834
DOI https://dx.doi.org/10.2174/157339406776872834 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression and Prognostic Significance of the MMP Family Molecules in Bladder Cancer
Combinatorial Chemistry & High Throughput Screening Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Current Management of Alcoholic Liver Disease
Current Drug Abuse Reviews Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8
Anti-Cancer Agents in Medicinal Chemistry Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a “Watch-and-Wait” Approach to Cancer
Current Stem Cell Research & Therapy Relevance of Drug Metabolizing Enzyme Activity Modulation by Tea Polyphenols in the Inhibition of Esophageal Tumorigenesis
Medicinal Chemistry A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Calpain-Associated Proteolytic Regulation of the Stromal Microenvironment in Cancer
Current Pharmaceutical Design Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets